Topiramate-Associated Movement Disorder: Case Series and Literature Review.

Abstract:

BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4). The mean age of the individuals (3 female patients) was 45.75 ± 21.28 years. All the individuals had a negative family history for movement and psychiatry disorders. Topiramate was started at 25 mg with a gradual increase of 25 mg every week. The mean time of onset and recovery of the MD were 1.37 ± 1.10 and 1.02 ± 0.77 months, respectively. The mean TPM dose was 87.5 ± 47.87 mg. Individual 1 presented with upper and lower limb jerks; individual 2 only with upper limb involvement. Individuals 3 and 4 experienced insomnia and nocturnal leg discomfort during inactivity with an urge to move the legs, which they denied having previously; the RLS symptoms occurred within approximately 1 to 3 hours of TPM evening dose. On neurological examination, no tremor or bradykinesia was observed; deep tendon reflexes, sensory examination, and strength were normal and preserved. Laboratory tests, neuroimaging, and electromyography were within normal. Topiramate was discontinued in all of the subjects. Full recovery was obtained in all cases. CONCLUSIONS:To the authors' knowledge, there are 6 cases of myoclonus, 5 RLS, 2 dystonia, 1 dyskinesia, and 1 periodic limb MD. The best management is probably the discontinuation of TPM, but in RLS patients, the addition of a dopaminergic agonist can be beneficial.

journal_name

Clin Neuropharmacol

authors

Rissardo JP,Caprara ALF

doi

10.1097/WNF.0000000000000395

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

116-120

issue

4

eissn

0362-5664

issn

1537-162X

journal_volume

43

pub_type

杂志文章
  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Beneficial effect of fluoxetine in a case of sporadic hyperekplexia.

    abstract::We studied a 67-year-old woman with a sporadic form of hyperekplexia, who experienced 8-10 excessive startle responses to unexpected stimuli per month. Therapy with fluoxetine had a definite beneficial effect. This finding supports the hypothesis that serotonergic mechanisms play a role in this disorder. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200005000-00006

    authors: Sechi G,Sotgiu S,Valenti MP,Pitzolu MG,Peterlongo P,Larizza L,Rosati G

    更新日期:2000-05-01 00:00:00

  • Assessing neuropsychological changes in pharmacological trials.

    abstract::This article outlines the reasons that detection of subtle changes in the cognitive system is difficult in geriatric assessment. A new assessment approach is introduced that examines cognitive patterns and facilitates the evaluation of subtle changes. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199316001-00005

    authors: Poon LW

    更新日期:1993-01-01 00:00:00

  • Severe weight gain induced by combination treatment with risperidone and paroxetine.

    abstract::Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200209000-00009

    authors: Fukui H,Murai T

    更新日期:2002-09-01 00:00:00

  • Clinical implications of sustained dopaminergic stimulation.

    abstract::Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

    更新日期:1994-01-01 00:00:00

  • New treatment strategies for bacterial meningitis.

    abstract::Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199310000-00001

    authors: Roos KL

    更新日期:1993-10-01 00:00:00

  • Parkinsonism in Patients With Chronic Hepatitis C Treated With Interferons: Case Reports and Review of the Literature.

    abstract::Interferons are a set of cytokines that activate antiviral responses by the body's immune cells and have been a mainstay of treatment of hepatitis C. Well-known neuropsychiatric effects of interferons include depression, irritability, and impaired concentration. A condition reported rarely in association with this tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0000000000000120

    authors: Wangensteen KJ,Krawitt EL,Hamill RW,Boyd JT

    更新日期:2016-01-01 00:00:00

  • Antiepileptic drugs in posttraumatic stress disorder.

    abstract::Antiepileptic drugs might be effective in the treatment of patients with Posttraumatic Stress Disorder, a condition with unmet pharmacologic needs. We review the literature on the efficacy and tolerability of antiepileptic drugs in Posttraumatic Stress Disorder, both case reports and open studies, as well as controlle...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200207000-00006

    authors: Iancu I,Rosen Y,Moshe K

    更新日期:2002-07-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage.

    abstract:BACKGROUND:The cerebellum has traditionally been regarded as an organ of motor coordination. However, the importance of the cerebellum in psychiatric disorders, behavior, and cognition is increasingly being recognized. There is no consensus concerning treatment of schizophrenia-like psychosis after cerebellar pathology...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31821f4d91

    authors: Almeida J,Serrão EM,Almeida AT,Afonso JG

    更新日期:2011-05-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • L-tyrosine pharmacotherapy of schizophrenia: preliminary data.

    abstract::The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199402000-00006

    authors: Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

    更新日期:1994-02-01 00:00:00

  • Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration.

    abstract::In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199502000-00012

    authors: Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

    更新日期:1995-02-01 00:00:00

  • Lithium and male sexual function in affective patients.

    abstract::The aim of the present study was to evaluate sexual function and behaviour in male patients who take lithium. Participants included 35 bipolar and schizoaffective men, aged 43.3 +/- 9.6 years, who were in euthymic state and were receiving lithium as the sole medical treatment. Eleven patients (31.4%) reported sexual d...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199619060-00005

    authors: Aizenberg D,Sigler M,Zemishlany Z,Weizman A

    更新日期:1996-12-01 00:00:00

  • Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms.

    abstract:OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/WNF.0b013e3180986d43

    authors: Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

    更新日期:2008-03-01 00:00:00

  • Treatment of Tourette's syndrome with calcium antagonists.

    abstract::Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199002000-00008

    authors: Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

    更新日期:1990-02-01 00:00:00

  • Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

    abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000110

    authors: Ohta K,Osada T

    更新日期:2015-11-01 00:00:00

  • A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.

    abstract::This review examines the features of the 16 randomized controlled trials that have been published on the use of oral tacrine for treating probable Alzheimer's disease and explores the methodologic problems associated with these studies. Patient selection using the standard National Institute of Neurological and Commun...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Conway EL

    更新日期:1998-01-01 00:00:00

  • Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.

    abstract:OBJECTIVES:IPX066 is an oral, extended-release capsule formulation of carbidopa-levodopa (CD-LD) available in 4 strengths. The goals of this investigation were to assess the dose proportionality of IPX066 and to study the effects of a high-fat, high-calorie meal and of sprinkling the capsule contents on applesauce on t...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000126

    authors: Yao HM,Hsu A,Gupta S,Modi NB

    更新日期:2016-01-01 00:00:00

  • Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

    abstract::A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199310000-00004

    authors: Gomez-Mancilla B,Bédard PJ

    更新日期:1993-10-01 00:00:00

  • Acute dystonic reaction in normal humans caused by catecholamine depletion.

    abstract::Five of 24 (21%) normal men (volunteers) administered alpha-methyl-para-tyrosine (AMPT), a catecholamine-depleting agent, developed acute dystonic reactions. The finding that catecholamine depletion without receptor blockade is sufficient to cause acute dystonia suggests that a variety of neurotransmitter imbalances m...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00009

    authors: McCann UD,Penetar DM,Belenky G

    更新日期:1990-12-01 00:00:00

  • Poor tolerability of a transdermal nicotine treatment in Parkinson's disease.

    abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200309000-00004

    authors: Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

    更新日期:2003-09-01 00:00:00

  • Gabapentin treatment for muscle cramps: an open-label trial.

    abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200001000-00008

    authors: Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

    更新日期:2000-01-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198406000-00006

    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

    abstract::The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318223421f

    authors: da Rocha FF,Correa H

    更新日期:2011-07-01 00:00:00

  • Treatment of psychogenic polydipsia with acetazolamide: a report of 5 cases.

    abstract:OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318205070b

    authors: Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

    更新日期:2011-01-01 00:00:00

  • Treatment of primary progressive freezing of gait with high doses of selegiline.

    abstract::We report the case of a 76-year-old, right-handed woman with progressive primary freezing of gait. Despite several therapeutic strategies, she continued to worsen to the point that she became confined to a wheelchair. Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder. This...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200601000-00007

    authors: Zúñiga C,Lester J,Cersósimo MG,Díaz S,Micheli FE

    更新日期:2006-01-01 00:00:00

  • Place of dexfenfluramine in the management of obesity.

    abstract::The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Guy-Grand BJ

    更新日期:1988-01-01 00:00:00

  • Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors.

    abstract::Following oral administration in the fasting healthy subject, the mean maximum concentration of tianeptine is 334 +/- 79 ng/ml. Absorption of tianeptine from the tablet form is rapid and complete. Maximum plasma concentration is obtained by the first hour following administration (0.94 +/- 0.47 h). Absolute bioavailab...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Royer RJ,Albin H,Barrucand D,Salvadori-Failler C,Kamoun A

    更新日期:1988-01-01 00:00:00

  • Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia.

    abstract:BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/wnf.0b013e3180674e0e

    authors: Parrino L,Smerieri A,Giglia F,Milioli G,De Paolis F,Terzano MG

    更新日期:2008-01-01 00:00:00